Aportaciones científicas más relevantes del XVII Congreso de la Sociedad Europea de Hipertensión. Milán, 15-19 de junio de 2007

2007, 2007 Guidelines for the Management of Arterial Hypertension, J Hypertens, 25, 1105, 10.1097/HJH.0b013e3281fc975a 2003, 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J Hypertens, 21, 1011, 10.1097/00004872-200306000-00001 Chobanian, 2003, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2 D’Agostino, 2001, Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation, JAMA, 286, 180, 10.1001/jama.286.2.180 Conroy, 2003, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, Eur Heart J, 24, 987, 10.1016/S0195-668X(03)00114-3 Ford, 2005, Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence, Diabetes Care, 28, 1769, 10.2337/diacare.28.7.1769 De la Sierra, 2006, Valor de la presión de pulso como marcador de riesgo cardiovascular, Med Clin (Barc), 124, 384 2003, Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?, Diabetes Care, 26, 688, 10.2337/diacare.26.3.688 Boutouyrie, 2002, Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. A longitudinal study, Hypertension, 39, 10, 10.1161/hy0102.099031 Brosius, 2006, Developed in Collaboration With the National Kidney Foundation, Circulation, 114, 1083, 10.1161/CIRCULATIONAHA.106.177321 Williams, 2004, Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV, J Human Hypertens, 18, 139, 10.1038/sj.jhh.1001683 Lindholm, 2005, Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis, Lancet, 366, 1545, 10.1016/S0140-6736(05)67573-3 Bradley, 2006, How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis, J Hypertens, 24, 2131, 10.1097/01.hjh.0000249685.58370.28 Banegas, 2007, Effectiveness of blood pressure control outside the medical setting, Hypertension, 49, 62, 10.1161/01.HYP.0000250557.63490.55 Gorostidi, 2007, Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in Spain, J Hypertens, 25, 977, 10.1097/HJH.0b013e32809874a2 Sierra, 2007, Monitorización ambulatoria de la presión arterial (MAPA): características clínicas de 31.530 pacientes, Med Clin (Barc), 129, 1, 10.1157/13106673 Staessen, 2006, Oral renin inhibitors, Lancet, 368, 1449, 10.1016/S0140-6736(06)69442-7 De la Sierra, 2007, Inhibidores de la renina, Med Clin (Barc), 128, 214, 10.1016/S0025-7753(07)72540-X De la Sierra, 2006, Angiotensin receptor blockers in hypertension and cardiovascular diseases, Cardiovasc Hematol Agents Med Chem, 4, 67, 10.2174/187152506775268839 Sierra, 2005, Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin receptor blockers, Curr Opin Nephrol Hypertens, 14, 435, 10.1097/01.mnh.0000174397.59100.89 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Sever, 2006, Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial, Eur Heart J, 27, 2982, 10.1093/eurheartj/ehl403 De la Sierra, 2007, Management of cardiovascular risk factors in patients with metabolic syndrome, Cardiovasc Hematol Agents Med Chem, 5, 209, 10.2174/187152507781058690